Universal Biosensors (ASX:UBI) ROE % Adjusted to Book Value : -41.54% (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Universal Biosensors ROE % Adjusted to Book Value?

Universal Biosensors's ROE % for the quarter that ended in Dec. 2024 was -75.18%. Universal Biosensors's PB Ratio for the quarter that ended in Dec. 2024 was 1.81. Universal Biosensors's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -41.54%.

Universal Biosensors ROE % Adjusted to Book Value Historical Data

The historical data trend for Universal Biosensors's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Biosensors ROE % Adjusted to Book Value Chart

Universal Biosensors Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-9.02

-5.01

-54.66

-13.63

-42.67

Universal Biosensors Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-15.84	-29.18	-38.53	-28.14	-41.54

Competitive Comparison of Universal Biosensors's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Universal Biosensors's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Biosensors's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Universal Biosensors's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Universal Biosensors's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Universal Biosensors ROE % Adjusted to Book Value Calculation

Universal Biosensors's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-77.23%	/	1.81
	=	-42.67%

Universal Biosensors's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-75.18%	/	1.81
	=	-41.54%

Universal Biosensors ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Universal Biosensors's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Universal Biosensors Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Universal Biosensors Inc (ASX:UBI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Corporate Avenue, Rowville, VIC, AUS, 3178

Website

https://www.universalbiosensors.com

Universal Biosensors Inc is biosensor company in electrochemical cell technology to develop a diverse range of biosensor test strips. The company's platform develops a diverse range of biosensor test strips used in conjunction with point-of-use devices that are used in various industries such as healthcare (point-of-care), wine, food and agriculture. It manufactures and distributes PT-INR coagulation test strips and devices, Xprecia, Stride and Xprecia Prime which are medical devices, Sentia non-medical wine testing products, and Petrackr which is a blood glucose test used in cats and dogs. It has one reportable segment: specialist biosensors company. Geographically, the company generates majority of its revenue from Australia and rest from Americas, Europe and other markets.

Universal Biosensors Headlines

No Headlines